A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G

European Urology

Volumn 68, Issue 2, 2015, Pages 267-279

  Carosella, Edgardo D ^a,b   Ploussard, Guillaume ^a   LeMaoult, Joel ^a,b   Desgrandchamps, Francois ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Cancer immunotherapy; Checkpoint; CTLA 4; HLA G; Monoclonal antibodies; PD 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA G ANTIGEN; IPILIMUMAB; NIVOLUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SUNITINIB; TICILIMUMAB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLITIS; COLON PERFORATION; CYSTECTOMY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS; HUMAN; HYPOPHYSITIS; IRITIS; KIDNEY CANCER; MONOTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SYSTEMATIC REVIEW; URINARY TRACT CANCER; UVEITIS; VITILIGO; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UROLOGIC NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HLA-G ANTIGENS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UROLOGIC NEOPLASMS;

EID: 84937516588     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.02.032     Document Type: Review

References (75)

1. A.V. Collins, D.W. Brodie, R.J.C. Gilbert, and et al. The interaction properties of costimulatory molecules revisited Immunity 17 2002 201 210
2. C.E. Rudd, A. Taylor, and H. Schneider CD28 and CTLA-4 coreceptor expression and signal transduction Immunol Rev 229 2009 12 26
3. W.A. Teft, M.G. Kirchhof, and J. Madrenas A molecular perspective of CTLA-4 function Annu Rev Immunol 24 2006 65 97
4. D.J. Lenschow, T.L. Walunas, and J.A. Bluestone CD28/B7 system of T cell costimulation Annu Rev Immunol 14 1996 233 258
5. + regulatory T cell function Science 322 2008 271 275
6. A.A. Hurwitz, B.A. Foster, E.D. Kwon, and et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res 60 2000 2444 2448
7. S. Demaria, N. Kawashima, A.M. Yang, and et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer Clin Cancer Res 11 2005 728 734
8. S. Wada, C.M. Jackson, K. Yoshimura, and et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer J Transl Med 11 2013 89
9. S.F. Slovin, C.S. Higano, O. Hamid, and et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813 1821
10. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815
11. L. Fong, S.S. Kwek, S. O'Brien, and et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF Cancer Res 69 2009 609 615
12. R.A. Madan, M. Mohebtash, P.M. Arlen, and et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 2012 501 508
13. C. Jochems, J.A. Tucker, K.Y. Tsang, and et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates Cancer Immunol Immunother 63 2014 407 418
14. A.J.M. van den Eertwegh, J. Versluis, H.P. van den Berg, and et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 2012 509 517
15. + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment Cancer Immunol Immunother 62 2013 245 256
16. E.D. Kwon, C.G. Drake, H.I. Scher, and et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 700 712
17. D.G. McNeel, H.A. Smith, J.C. Eickhoff, and et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer Cancer Immunol Immunother 61 2012 1137 1147
18. J.C. Yang, M. Hughes, U. Kammula, and et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
19. J.A. Blansfield, K.E. Beck, K. Tran, and et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer J Immunother 28 2005 593 598
20. B.I. Rini, M. Stein, P. Shannon, and et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma Cancer 117 2011 758 767
21. L. Wang, G. Su, X. Zhao, and et al. Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk Tumour Biol 35 2014 1139 1142
22. B.C. Carthon, J.D. Wolchok, J. Yuan, and et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 2010 2861 2871
23. G.J. Freeman, A.J. Long, Y. Iwai, and et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
24. S.-Y. Tseng, M. Otsuji, K. Gorski, and et al. B7-Dc, a New dendritic cell molecule with potent costimulatory properties for T cells J Exp Med 193 2001 839 846
25. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 1992 3887 3895
26. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
27. H. Dong, S.E. Strome, D.R. Salomao, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
28. T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 2013 1212 1218
29. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
30. + Prostate 69 2009 1694 1703
31. I. Roth, D.B. Corry, R.M. Locksley, J.S. Abrams, M.J. Litton, and S.J. Fisher Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10 J Exp Med 184 1996 539 548
32. P.A. Tang, and D.Y. Heng Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer Curr Oncol Rep 15 2013 98 104
33. R.H. Thompson, H. Dong, and E.D. Kwon Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy Clin Cancer Res 13 2007 709s-15s
34. A.E. Krambeck, H. Dong, R.H. Thompson, and et al. Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma Clin Cancer Res 13 2007 1749 1756
35. J.R. Brahmer, C.G. Drake, I. Wollner, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
36. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
37. D.C. Cho, J.A. Sosman, M. Sznol, and et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) ASCO Meeting Abstr 31 2013 4505
38. R.J. Motzer, B.I. Rini, D.F. McDermott, and et al. Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma Ann Oncol 25 Suppl 4 2014 iv281
39. A. Amin, E.R. Plimack, J.R. Infante, and et al. Nivolumab in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma Ann Oncol 25 Suppl 4 2014 iv362-3
40. T.K. Choueiri, D.J. Figueroa, A.P. Fay, and et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial Clin Cancer Res 21 2015 1071 1077
41. R.S. Herbst, J.-C. Soria, M. Kowanetz, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
42. J. Nakanishi, Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunol Immunother 56 2007 1173 1182
43. B.A. Inman, T.J. Sebo, X. Frigola, and et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression Cancer 109 2007 1499 1505
44. E. Xylinas, B.D. Robinson, L.A. Kluth, and et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder Eur J Surg Oncol 40 2014 121 127
45. S.A. Boorjian, Y. Sheinin, P.L. Crispen, and et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival Clin Cancer Res 14 2008 4800 4808
46. E.R. Plimack, S. Gupta, J. Bellmunt, and et al. A phase Ib study of pembrolizumab in patients with advanced urothelial tract cancer Ann Oncol 25 Suppl 4 2014 mdu438.24
47. J. Bellmunt, D.P. Petrylak, T. Powles, and et al. Inhibition of PD-L1 by MPDL3208a leads to clinical activity in patients with metastatic urothelial bladder cancer Ann Oncol 25 Suppl 4 2014 iv280
48. T. Powles, J.P. Eder, G.D. Fine, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
49. E.D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. Lemaoult Beyond the increasing complexity of the immunomodulatory HLA-G molecule Blood 111 2008 4862 4870
50. E.D. Carosella, S. Gregori, and J. LeMaoult The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells Blood 118 2011 6499 6505
51. E.D. Carosella, P. Moreau, J. Lemaoult, and N. Rouas-Freiss HLA-G: from biology to clinical benefits Trends Immunol 29 2008 125 132
52. N. Rouas-Freiss, P. Moreau, J. LeMaoult, and E.D. Carosella The dual role of HLA-G in cancer J Immunol Res 2014 359748
53. A. Lin, X. Zhang, H.H. Xu, D.P. Xu, Y.Y. Ruan, and W.H. Yan HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer Int J Cancer 131 2012 150 157
54. B.L. Li, A. Lin, X.J. Zhang, and et al. Characterization of HLA-G expression in renal cell carcinoma Tissue Antigens 74 2009 213 221
55. J. Bukur, V. Rebmann, H. Grosse-Wilde, and et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma Cancer Res 63 2003 4107 4111
56. F.A. El-Chennawi, F.A. Auf, A.M. El-Diasty, and et al. Expression of HLA-G in cancer bladder Egypt J Immunol 12 2005 57 64
57. L.H. Gan, L.F. Huang, X. Zhang, and et al. Tumor-specific upregulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma Hum Immunol 71 2010 899 904
58. L. Wang, F.-B. Kang, and B.-E. Shan B7-H3-mediated tumor immunology: friend or foe? Int J Cancer 134 2014 2764 2771
59. S. Ceeraz, E.C. Nowak, and R.J. Noelle B7 family checkpoint regulators in immune regulation and disease Trends Immunol 34 2013 556 563
60. J. Jiang, Y. Zhu, C. Wu, and et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer Cancer Immunol Immunother 59 2010 1707 1714
61. A.E. Krambeck, R.H. Thompson, H. Dong, and et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival Proc Natl Acad Sci U S A 103 2006 10391 10396
62. B. Tringler, S. Zhuo, G. Pilkington, and et al. B7-H4 is highly expressed in ductal and lobular breast cancer Clin Cancer Res 11 2005 1842 1848
63. W.J. Norde, W. Hobo, R. van der Voort, and H. Dolstra Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention Blood 120 2012 728 736
64. S.F. Ngiow, M.W.L. Teng, and M.J. Smyth Prospects for TIM3-targeted antitumor immunotherapy Cancer Res 71 2011 6567 6571
65. Y. Liu, L. Vlatkovic, T. Saeter, and et al. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Int J Urol 19 2012 749 756
66. H. Yuan, X. Wei, G. Zhang, C. Li, X. Zhang, and J. Hou B7-H3 over expression in prostate cancer promotes tumor cell progression J Urol 186 2011 1093 1099
67. A.S. Parker, M.G. Heckman, Y. Sheinin, and et al. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer Int J Radiat Oncol Biol Phys 79 2011 1343 1349
68. T.J. Roth, Y. Sheinin, C.M. Lohse, and et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy Cancer Res 67 2007 7893 7900
69. C. Brignone, B. Escudier, C. Grygar, M. Marcu, and F. Triebel A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma Clin Cancer Res 15 2009 6225 6231
70. X. Qin, H. Zhang, D. Ye, B. Dai, Y. Zhu, and G. Shi B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma Onco Targets Ther 6 2013 1667 1673
71. P.L. Crispen, Y. Sheinin, T.J. Roth, and et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma Clin Cancer Res 14 2008 5150 5157
72. K.E. Beck, J.A. Blansfield, K.Q. Tran, and et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol 24 2006 2283 2289
73. D.E. Dolan, and S. Gupta PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy Cancer Control 21 2014 231 237
74. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
75. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 2010 4275 4280